Replicon RNA viral vectors as vaccines

Vaccines

Volumn 4, Issue 4, 2016, Pages

  Lundstrom, Kenneth ^a  

^a Pan Therapeutics   (Switzerland)

Author keywords

Alphaviruses; Antibodies; Disease protection; Flaviviruses; Infectious diseases; Measles viruses; Rhabdoviruses; Tumors

Indexed keywords

BETA GALACTOSIDASE; CALRETICULIN; CARCINOEMBRYONIC ANTIGEN; CD150 ANTIGEN; ENDOSTATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAG PROTEIN; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 18; LIPOSOME; MATRIX PROTEIN; MICRORNA 124; NEUTRALIZING ANTIBODY; POLYPROTEIN; PROSTATE SPECIFIC ANTIGEN; RNA POLYMERASE; SODIUM IODIDE SYMPORTER; SURVIVIN; VASCULOTROPIN C; VIRUS VACCINE;

ADENOVIRIDAE; ALPHAVIRUS; BREAST CANCER; CANCER IMMUNOTHERAPY; ENCAPSULATION; EXPRESSION VECTOR; FLAVIVIRUS; GENE EXPRESSION; GENE EXPRESSION SYSTEM; GENE TARGETING; GENETIC ENGINEERING; HERPES SIMPLEX VIRUS; HUMAN; IMMUNE RESPONSE; KIDNEY CARCINOMA; LENTIVIRINAE; MEASLES VIRUS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROVIRIDAE; REVIEW; RHABDOVIRIDAE; RNA VIRUS; VACCINIA VIRUS; VIRUS TRANSCRIPTION;

EID: 85016904554     PISSN: None     EISSN: 2076393X     Source Type: Journal    
DOI: 10.3390/vaccines4040039     Document Type: Review

References (136)

1. Delrue, I., Verzele, D., Madder, A., Nauwynck, H.J. Inactivated virus vaccines: From chemistry to prophylaxis: Merits, risks and challenges. Expert Rev. Vaccines 2012, 11, 695-719. [CrossRef]
2. Deng, M.P., Hu, Z.H., Wan, H.L., Deng, F. Developments of subunit and VLP vaccines against influenza A virus. Virol. Sin. 2012, 27, 145-153. [CrossRef]
3. Apostolopoulos, V. Vaccine delivery methods into the future. Vaccines 2016. [CrossRef]
4. Lundstrom, K. Alphavirus-based vaccines. Viruses 2014, 6, 2392-2415. [CrossRef]
5. Schmidt, S.T., Foged, C., Korsholm, K.S., Rades, T., Christensen, D. Liposome-based adjuvants for subunit vaccines: Formulation strategies for subunit antigens and immunostimulators. Pharmaceutics 2016. [CrossRef]
6. Cibulski, S.P., Mourglia-Ettlin, G., Teixeira, T.F., Quirici, L., Roehe, P.M., Ferreira, F., Silveira, F. Novel ISCOMs from Quillaja brasiliensis saponins induce mucosal and systemic antibody production, T-cell responses and improved antigen uptake. Vaccine 2016, 34, 1162-1171. [CrossRef]
7. Sheng, K.C., Kalkanidis, M., Pouniotis, D.S., Esparon, S., Tang, C.K., Apostolopoulos, V., Pietersz, G.A. Delivery of antigen using a novel mannosylated dendrimer potentiates immunogenicity in vitro and in vivo. Eur. J. Immunol. 2008, 38, 424-436. [CrossRef]
8. Lundstrom, K. Alphaviruses in gene therapy. Viruses 2015, 7, 2321-2333. [CrossRef]
9. Lundstrom, K. Self-replicating RNA viral vectors in vaccine development and gene therapy. Future Virol. 2016, 11, 345-356. [CrossRef]
10. Lyles, D.S., Rupprecht, C.E. Rhabdoviridiae. In Fields’ Virology, Knipe, D.M., Howley, P.M., Eds., Wolters Kluwer: Philadelphia, PA, USA, 2007, pp. 1364-1408.
11. Rima, B.K., Duprex,W.P. The measles virus replication cycle. Curr. Top. Microbiol. Immunol. 2009, 329, 77-102.
12. Brinton, M.A. Replication cycle and molecular biology of West Nile virus. Viruses 2013, 6, 13-53. [CrossRef]
13. Westaway, E.G., Mckenzie, J.M., Khromykh, A.A. Kunjin RNA replication and applications of Kunjin replicons. Adv. Virus Res. 2003, 59, 99-140.
14. Liljestrom, P., Garoff, H. A new generation of animal cell expression vectors based on the Semliki Forest virus replicon. Biotechnology 1991, 9, 1356-1361. [CrossRef]
15. Xiong, C., Levis, R., Shen, P., Schlesinger, S., Rice, C.M., Huang, H.V. Sindbis virus: An efficient, broad host range vector for gene expression in animal cells. Science 1989, 243, 1188-1191. [CrossRef]
16. Davis, N.L., Willis, L.V., Smith, J.F., Johnston, R.E. In vitro synthesis of infectious Venezuelan equine encephalitis virus RNA from a cDNA clone: Analysis of a viable deletion mutant. Virology 1989, 171, 189-204. [CrossRef]
17. Strauss, J.H., Strauss, E.G. The Alphaviruses: Gene Expression, Replication and Evolution. Micobiol. Rev. 1994, 58, 491-562.
18. Pijlman, G.P., Suhrbier, A., Khromykh, A.A. Kunjin virus replicons: An RNA-based, non-cytopathic viral vector system for protein production, vaccine and gene therapy applications. Exp. Opin. Biol. Ther. 2006, 6, 134-145. [CrossRef]
19. Shi, P.Y., Tilgner, M., Lo, M.K. Construction and characterization of subgenomic replicons of New York strain of West Nile virus. Virology 2002, 296, 219-233. [CrossRef]
20. Scholle, I., Girard, Y.A., Zhao, Q., Higgs, S., Mason, P.W. Trans-packaged West Nile virus-like particles: Infectious properties in vitro and in infected mosquito vectors. J. Virol. 2004, 78, 11605-11614. [CrossRef]
21. Molenkamp, R., Kooi, E.A., Lucassen, M.A., Greve, S., Thijssen, J.C., Spaan, W.J., Bredenbeek, P.J. Yellow fever virus replicons as an expression system for hepatitis C virus structural proteins. J. Virol. 2003, 77, 1644-1648. [CrossRef]
22. Jones, C.T., Patkar, C.G., Kuhn, R.J. Construction and applications of yellow fever virus replicons. Virology 2005, 331, 247-259. [CrossRef]
23. Jones, M., Davidson, A., Hibbert, L., Gruenwald, P., Schlaak, J., Ball, S., Foster, G.R., Jacobs, M. Dengue virus inhibits alpha interferon signaling by reducing STAT2 expression. J. Virol. 2005, 79, 5414-5420. [CrossRef]
24. Pang, X., Zhang, M., Dayton, A.I. Development of Dengue virus Type 2 replicons capable of prolonged expression in host cells. BMC Microbiol. 2001. [CrossRef]
25. Gherke, R., Ecker, M., Aberle, S.W., Allison, S.L., Heinz, F.X., Mandi, C.W. Incorporation of tick-borne encephalitis virus replicons into virus-like particles by a packaging cell line. J. Virol. 2003, 77, 8924-8933. [CrossRef]
26. Hayasaka, D., Yoshii, K., Ueki, T., Iwasaki, T., Takashima, I. Sub-genomic replicons of Tick-borne encephalitis virus. Arch.Virol. 2004, 149, 1245-1256. [CrossRef]
27. Khromykh, A.A., Varnavski, A.N., Westaway, E.G. Encapsidation of the flavivirus kunjin replicon RNA by using a complementation system providing Kunjin virus structural proteins in trans. J. Virol. 1998, 72, 5967-5977.
28. De Felipe, F. Skipping the co-expression problem: The new2A “CHYSEL” technology. Genet. Vaccines Ther. 2004. [CrossRef]
29. Radecke, F., Spielhofer, P., Schneider, H., Kaelin, K., Huber, M., Dötsch, C., Christiansen, G., Billeter, M.A. Rescue of measles viruses from cloned DNA. EMBO J. 1995, 14, 5773-5784.
30. Singh, M., Cattaneo, R., Billeter, M.A. A recombinant measles virus expressing hepatitis B surface antigen induces humoral responses in genetically modified mice. J. Virol. 1999, 73, 4823-4828.
31. Ito, N., Takayama-Ito, M., Yamada, K., Hosokawa, J., Sugiyama, M., Minamoto, N. Improved recovery of rabies virus from cloned cDNA using a vaccinia virus-free reverse genetics system. Microbiol. Immunol. 2003, 47, 613-617. [CrossRef]
32. Harty, R.N., Brown, M.E., Hayes, F.P., Wright, N.T., Schnell, M.J. Vaccinia virus-free recovery of vesicular stomatitis virus. J. Mol. Microbiol. Biotechnol. 2001, 3, 513-517.
33. An, H., Kim, G.N., Kang, C.Y. Genetically modified VSV(NJ) vector is capable of accommodating a large foreign gene insert and allows high level gene expression. Virus Res. 2013, 171, 168-177. [CrossRef]
34. Dorange, F., Piver, E., Bru, T., Collin, C., Roingeard, P. Vesicular stomatitis virus glycoprotein: A transducing coat for SFV-based RNA vectors. J. Gene Med. 2004, 6, 1014-1022. [CrossRef]
35. Malone, J.G., Berglund, P.J., Liljestrom, P., Rhodes, G., Malone, R.W. Mucosal immune responses associated with polynucleotide vaccination. Behring Inst. Mitt. 1997, 98, 63-72.
36. Schultz-Cherry, S., Dybing, J.K., Davis, N.L., Williamson, C., Suarez, D.L., Johnston, R., Perdue, M.L. Influenza virus (A/HK/156/97) hemagglutinin expressed by an alphavirus replicon system protects against lethal infection with Hong Kong-origin H5N1 viruses. Virology 2000, 278, 55-59. [CrossRef]
37. Bosworth, B., Erdman, M.M., Stine, D.L., Harris, I., Irwin, C., Jens, M., Loynachan, A., Kamrud, K., Harris, D.L. Replicon particle vaccine protects swine against influenza. Comp. Immunol. Microbiol. Infect. Dis. 2010, 33, e99-e103. [CrossRef]
38. Vander Veen, R.L., Loynachan, A.T., Mogler, M.A., Russell, B.J., Harris, D.L., Kamrud, K. Safety, immunogenicity and efficacy of an alphavirus replicon-based swine influenza virus hemagglutinin vaccine. Vaccine 2012, 30, 1944-1950. [CrossRef]
39. Sweft-Tapia, C., Bogaert, L., de Jong, P., van Hoek, V., Schouten, T., Damen, I., Spek, D., Wanningen, P., Radosevic, K., Zahn, R., et al. Recombinant measles virus incorporating heterlogous viral membrane proteins for use as vaccines. J. Gen. Virol. 2016, 97, 2117-2128. [CrossRef]
40. Ryder, A.B., Nachbaqauer, R., Buonocore, L., Palese, P., Krammer, F., Rose, J.K. Vaccination with Vesicular Stomatitis virus-vectored chimeric hemagglutinins protects mice against divergent influenza virus challenge strains. J. Virol. 2015, 90, 2544-2550. [CrossRef]
41. Harvey, T.J., Anraku, I., Linedale, R., Harrich, D., Mackenzie, J., Suhrbier, A., Khromykh, A.A. Kunjin virus replicon vectors for human immunodefiency virus vaccine development. J. Virol. 2003, 77, 7796-7803. [CrossRef]
42. Brand, D., Lemiale, F., Turbica, I., Buzelay, L., Brunet, S., Barin, F. Comparative analysis of humoral immune responses to HIV type 1 envelope glycoproteins in mice immunized with a DNA vaccine, recombinant Semliki Forest virus RNA, or recombinant Semliki Forest virus particles. AIDS Res. Hum. Retrovir. 1998, 14, 1369-1377. [CrossRef]
43. Giraud, A., Ataman-Onal, Y., Battail, N., Piga, N., Brand, D., Mandrand, B., Vernier, B. Generation of monoclonal antibodies to native human immunodeficiency virus type 1 envelope glycoprotein by immunization of mice with naked RNA. J. Virol. Methods 1999, 79, 75-84. [CrossRef]
44. Knudsen, M.L., Ljungberg, K., Tatoud, R., Weber, J., Esteban, M., Liljestrom, P. Alphavirus replicon DNA expressing HIV antigens is an excellent prime for boosting with recombinant modified vaccinia Ankara (MVA) or with HIV gp140 protein antigen. PLoS ONE 2015, 10, e0117042. [CrossRef]
45. Anraku, I., Mokhonov, V.V., Rattanasena, P., Mokhonova, E.I., Leung, J., Pijlman, G., Cara, A., Schroeder, W.A., Khromykh, A.A., Suhrbier, A. Kunjin replicon-based simian immunodeficiency virus gag vaccines. Vaccine 2008, 26, 3268-3276. [CrossRef]
46. Schell, J.B., Bahl, K., Folta-Stogniew, E., Rose, N., Buonocore, L., Marx, P.A., Gambhira, R.A., Rose, J.K. Antigenic requirement for Gag in a vaccine that protects against high-dose mucosal challenge with simian immunodeficiency virus. Virology 2015, 476, 405-412. [CrossRef]
47. Van Rompay, K.K., Abel, K., Earl, P., Kozlowski, P.A., Easlick, J., Moore, J., Buonocore-Buzzelli, L., Schmidt, K.A., Wilson, R.L., Simon, I., et al. Immunogenicity of viral vector, prime-boost SIV vaccine regimens in infant rhesus macaques: Attenuated vesicular stomatitis virus (VSV) and modified vaccinia Ankara (MVA) recombinant SIV vaccines compared to live-attenuated SIV. Vaccine 2010, 28, 1481-1492. [CrossRef]
48. McKenna, P.M., Koser, M.L., Carlson, K.R., Montefiori, D.C., Letvin, N.L., Papaneri, A.B., Pomerantz, R.J., Dietzschold, B., Silvera, P., McGettigan, J.P., et al. Highly attenuated rabies virus-based vaccine vectors expressing simian-human immunodeficiency virus89.6P Env and simian immunodeficiency virus mac239 Gag are safe in rhesus macaques and protect from an AIDS-like disease. J. Infect. Dis. 2007, 195, 980-988. [CrossRef]
49. Reynard, O., Mokhonov, V., Mokhonova, E., Leung, J., Page, A., Mateo, M., Pyankova, O., Georges-Courbot, M.C., Raoul, H., Khromykh, A.A., et al. Kunjin virus replicon-based vaccines expressing Ebola virus glycoprotein GP protect the guinea pig against lethal Ebola virus infection. J. Infect. Dis. 2011, 204, S1060-S1065. [CrossRef]
50. Pyankov, O.V., Bodnev, S.A., Pyankova, O.G., Solodkyi, V.V., Pyankov, S.A., Setoh, Y.X., Volchkova, V.A., Suhrbier, A., Volchkov, V.E., Agafonov, A.A., et al. A Kunjin replicon virus-like vaccine provides protection against Ebola virus infection in nonhuman primates. J. Infect.Dis. 2015, 212, S368-S371. [CrossRef]
51. Marzi, A., Robertson, S.J., Haddock, E., Feldmann, F., Hanley, P.W., Scott, D.P., Strong, J.E., Kobinger, G., Best, S.M., Feldmann, H. EBOLA VACCINE. VSV-EBOV rapidly protects macaques against infection with the 2014/2015 Ebola virus outbreak strain. Science 2015, 349, 739-742. [CrossRef]
52. Geisbert, T.W., Feldmann, H. Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg infections. J. Infect. Dis. 2011, 204, S1075-S1081. [CrossRef]
53. Pushko, P., Bray, M., Ludwig, G.V., Parker, M., Schmaljohn, A., Sanchez, A., Jahrling, P.B., Smith, J.F. Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus. Vaccine 2000, 19, 142-153. [CrossRef]
54. Wilson, J.A., Hart, M.K. Protection from Ebola virus mediated by cytotoxic T-lymphocytes specific for the viral nucleoprotein. J. Virol. 2001, 75, 2660-2664. [CrossRef]
55. Safronetz, D., Mire, C., Rosenke, K., Feldmann, F., Haddock, E., Geisbert, T., Feldmann, H. A recombinant Vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses. PLoS Negl. Trop. Dis. 2015, 9, e0003736. [CrossRef]
56. Pushko, P., Geisbert, J., Parker, M., Jahrling, P., Smith, J. Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses. J. Virol. 2001, 75, 11677-11685. [CrossRef]
57. Sheahan, T., Whitmore, A., Long, K., Ferris, M., Rockx, B., Funkhouser, D., Donaldson, E., Gralinski, L., Collier, M., Heise, M., et al. Successful vaccination strategies that protect aged mice from lethal challenge from influenza virus and heterologous severe acute respiratory syndrome coronavirus. J. Virol. 2011, 85, 217-230. [CrossRef]
58. Malczyk, A.H., Kupke, A., Prüfer, S., Scheuplein, V.A., Hutzler, S., Kreuz, D., Beissert, T., Bauer, S., Hubich-Rau, S., Tondera, C., et al. A Highly immunogenic and protective middle east respiratory syndrome coronavirus vaccine based on a recombinant measles virus vaccine platform. J. Virol. 2015, 89, 11654-11667. [CrossRef]
59. Geall, A.J., Verma, A., Otten, G.R., Shaw, C.A., Hekele, A., Banerjee, K., Cu, Y., Beard, C.W., Brito, L.A., Krucker, T., et al. Nonviral delivery of self-amplifying RNA vaccines. Proc. Natl. Acad. Sci. USA 2012, 109, 14604-14609. [CrossRef]
60. Bates, J.T., Pickens, J.A., Schuster, J.E., Johnson, M., Tollefson, S.J., Williams, J.V., Davis, N.L., Johnston, R.E., Schultz-Darken, N., Slaughter, J.C., et al. Immunogenicity and efficacy of alphavirus-derived replicon vaccines for respiratory syncytial virus and human metapneumovirus in nonhuman primates. Vaccine 2016, 34, 950-956. [CrossRef]
61. Harahap-Carrillo, I.S., Ceballos-Olvera, I., Valle, J.R. Immunogenic subviral particles displaying domain III of Dengue 2 envelope protein vectored by measles virus. Vaccines 2015, 3, 503-518. [CrossRef]
62. Hu, H.M., Chen, H.W., Hsiao, Y., Wu, S.H., Chung, H.H., Hsie, C.H., Chong, P., Leng, C.H., Pan, C.H. The successful induction of T-cell and antibody responses by a recombinant measles virus-vectored tetravalent dengue vaccine provides partial protection against dengue-2 infection. Hum. Vaccines Immunother. 2016. [CrossRef]
63. White, L.J., Sariol, C.A., Mattocks, M.D., Wahala, M.P.B.W., Yingsiwaphat, V., Collier, M.L., Whitley, J., Mikkelsen, R., Rodriguez, I.V., Martinez, M.I., et al. An alphavirus vector-based tetravalent dengue vaccine induces a rapid and protective immune response in macaques that differs qualitatively from immunity induced by live virus infection. J. Virol. 2013, 87, 3409-3424. [CrossRef]
64. Khalil, S.M., Tonkin, D.R., Mattocks, M.D., Snead, A.T., Johnston, R.E., White, L.J. A tetravalent alphavirus-vector based dengue vaccine provides effective immunity in an early life mouse model. Vaccine 2014, 32, 4068-4074. [CrossRef]
65. Reynolds, T.D., Buonocore, L., Rose, N.F., Rose, J.K., Robek, M.D. Virus-like vesicle-based therapeutic vaccine vectors for chronic hepatis B virus infection. J. Virol. 2015, 89, 10407-10415. [CrossRef]
66. Del Valle, J.R., Devaux, P., Hodge, G., Wegner, N.J., McChesney, M.B., Catteneo, R. A vectored measles virus induces hepatitis B surface antigen antibodies while protecting macaques against virus challenge. J. Virol. 2007, 81, 10597-10605. [CrossRef]
67. Bernstein, D.I., Reap, E.A., Katen, K., Watson, A., Smith, K., Norberg, P., Olmsted, R.A., Hoeper, A., Morris, J., Negri, S., et al. Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers. Vaccine 2009, 28, 484-493. [CrossRef]
68. Andersson, C., Vasconcelos, N.M., Sievertzon, M., Haddad, D., Liljeqvist, S. Comparative immunization study using RNA and DNA constructs encoding a part of the Plasmodium falciparum antigen Pf332. Scand. J. Immunol. 2001, 54, 117-124. [CrossRef]
69. Kirman, J.R., Turon, T., Su, H., Li, A., Kraus, C., et al. Enhanced immunogenicity to Mycobacterium tuberculosis by vaccination with an alphavirus plasmid replicon expressing antigen 85A. Infect. Immun. 2003, 71, 575-579. [CrossRef]
70. Li, N., Yu, Y.Z., Yu, W.Y., Sun, Z.W. Enhancement of the immunogenicity of DNA replicon vaccine of Clostridium botulinum neurotoxin serotype A by GM-CSF gene adjuvant. Immunopharmacol. Immunotoxicol. 2011, 33, 211-219. [CrossRef]
71. Cabrera, A., Sáez, D., Céspedes, S., Andrews, E., Oñate, A. Vaccination with recombinant Semliki Forest virus particles expressing translation initiation factor 3 of Brucella abortus induces protective immunity in BALB/c mice. Immunobiology 2009, 214, 467-474. [CrossRef]
72. Thomas, J.M., Moen, S.T., Gnade, B.T., Vargas-Inchaustegui, D.A., Foltz, S.M., Suarez, G., Heidner, H.W., König, R., Chopra, A.K., Peterson, J.W. Recombinant Sindbis virus vectors designed to express protective antigen of Bacillus anthracis protect animals from anthrax and display synergy with ciprofloxacin. Clin. Vaccine Immunol. 2009, 16, 1696-1699. [CrossRef]
73. Tsuji, M., Bergmann, C.C., Takita-Sonoda, Y., Murata, K., Rodrigues, E.G., Nussenzweig, R.S., Zavala, F. Recombinant Sindbis viruses expressing a cytotoxic T-lymphocyte epitope of a malaria parasite or of influenza virus elicit protection against the corresponding pathogen in mice. J. Virol. 1998, 72, 6907-6910.
74. Tober, R., Banki, Z., Egerer, L., Muik, A., Behmüller, S., Kreppel, F., Greczmiel, U., Oxenius, A., von Laer, D., Kimpel, J. VSV-GP: A potent viral vaccine vector that boosts the immune response upon repeated applications. J. Virol. 2014, 88, 4897-907. [CrossRef]
75. Krasemann, S., Jürgens, T., Bodemer, W. Generation of monoclonal antibodies against prion proteins with an unconventional nucleic acid-based immunization strategy. J. Biotechnol. 1999, 73, 119-129. [CrossRef]
76. Lee, J.S., Dyas, B.K., Nystrom, S.S., Lind, C.M., Smith, J.F., Ulrich, R.G. Immune protection against staphylococcal enterotoxin-induced toxic shock by vaccination with a Venezuelan equine encephalitis virus replicon. J. Infect. Dis. 2002, 185, 1192-1196. [CrossRef]
77. Marzi, A., Feldmann, F., Geisbert, T.W., Feldmann, H., Safronetz, D. Vesicular stomatitis virus-based vaccines against Lassa and Ebola viruses. Emerg. Infect. Dis. 2015, 21, 305-307. [CrossRef]
78. Tangy, F., Naim, H.Y. Live attenuated measles vaccine as a potential multivalent pediatric vaccination vector. Viral Immunol. 2005, 18, 317-26. [CrossRef]
79. Msaouel, P., Iankov, I.D., Dispenzieri, A., Galanis, E. Attenuated oncolysis measles virus strains as cancer therapeutics. Curr. Pharm. Biotechnol. 2012, 13, 1732-1741. [CrossRef]
80. Grote, D., Russell, S.J., Cornu, T.I., Cattaneo, R., Vile, R., Poland, G.A., Fielding, A.K. Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. Blood 2001, 97, 3746-3754. [CrossRef]
81. Hasegawa, K., Pham, L., O’Connor, M.K., Federspiel, M.J., Russell, S.J., Peng, K.W. Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter. Clin. Cancer Res. 2006, 12, 1868-1875. [CrossRef]
82. Paraskevakou, G., Allen, C., Nakamura, T., Zollman, P., James, C.D., Peng, K.W., Schroeder, M., Russll, S.J., Galanis, E. Epidermal growth factor receptor (EGFR)-retargeted measles virus strains effectively target EGFR-or EGFRvIII expressing gliomas. Mol. Ther. 2007, 15, 677-686. [CrossRef]
83. McDonald, C.J., Erlichman, C., Ingle, J.N., Rosales, G.A., Allen, C., Greiner, S.M., Harvey, M.E., Zollman, P.J., Russell, S.J., Galanis, E. A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer. Breast Cancer Res. Treat. 2006, 99, 177-184. [CrossRef]
84. Hastie, E., Grdzelishvili, V.Z. Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer. J. Gen. Virol. 2012, 93, 2529-2545. [CrossRef]
85. Murphy, A.M., Besmer, D.M., Moerdyk-Schauwecker, M., Moesti, N., Ornelles, D.A., Mukherjee, P., Grdzelishvili, V.Z. Vesicular stomatitis virus as an oncolytic agent against pancreatic ductal adenocarcinoma. J. Virol. 2012, 86, 3073-3087. [CrossRef]
86. Felt, S.A., Moerdyk-Schauwecker, M.J., Grdzelishvili, V.Z. Induction of apoptosis in pancreatic cancer cells by vesicular stomatitis virus. Virology 2015, 474, 163-173. [CrossRef]
87. Hoang-Le, D., Smeenk, L., Anraku, I., Pijlman, G.P., Wang, X.J., de Vrij, J., Liu, W.J., Lee, T.T., Schroeder, W.A., Khromykh, A.A., et al. A Kunjin replicon vector encoding granulocyte macrophage colony-stimulating factor for intra-tumoral gene therapy. Gene Ther. 2009, 16, 190-199. [CrossRef]
88. Herd, K.A., Harvey, T., Khromykh, A.A., Tindle, R.W. Recombinant Kunjin virus replicon vaccines induce protective T-cell immunity against human papillomavirus 16 E7-expressing tumour. Virology 2004, 319, 237-248. [CrossRef]
89. Yamanaka, R., Zullo, S.A., Ramsey, J., Onodera, M., Tanaka, R., Blaese, M., Xanthopoulos, K.G. Induction of therapeutic antitumor antiangiogenesis by intratumoral injection of genetically engineered endostatin-producing Semliki Forest virus. Cancer Gene Ther. 2001, 8, 796-802. [CrossRef]
90. Martikainen, M., Niittykoski, M., vonundzu Frauenberg, M., Immonen, A., Koponen, S., van Geenen, M., Vähä-Koskela, M., Ylösmäki, E., Jääskeläinen, J.E., Saksela, E., et al. MicroRNA-attenuated clone of virulent Semliki Forest virus overcomes antiviral type I interferon in resistant mouse CT-2A glioma. J. Virol. 2015, 89, 10637-10647. [CrossRef]
91. Yamanaka, R., Zullo, S.A., Tanaka, R., Ramsey, J., Blaese, M., Xanthopoulos, K.G. Induction of a therapeutic antitumor immunological response by intratumoral injection of genetically engineered Semliki Forest virus to produce interleukin-12. Neurosurg. Focus 2000, 9, e7. [CrossRef]
92. Yamanaka, R., Zullo, S.A., Ramsey, J., Yajima, N., Tsuchiya, N., Tanaka, R., Blaese, M., Xanthopoulos, K.G. Marked enhancement of antitumor immune responses in mouse brain tumor models by genetically modified dendritic cells producing Semliki Forest virus-mediated interleukin-12. J. Neurosurg. 2002, 97, 611-618. [CrossRef]
93. Roche, F.P., Sheahan, B.J., O’Mara, S.M., Atkins, G.J. Semliki Forest virus-mediated gene therapy of the RG2 rat glioma. Neuropathol. Appl. Neurobiol. 2010, 36, 648-660. [CrossRef]
94. Wang, X., Wang, J.P., Rao, X.M., Price, J.E., Zhous, H.S., Lachman, L.B. Prime-boost vaccination with plasmid and adenovirus gene vaccines control HER2/neu+ metastatic breast cancer in mice. Breast Cancer Res. 2005, 7, R580-R588. [CrossRef]
95. Moran, T.P., Burgents, J.E., Long, B., Ferrer, I., Jaffee, E.M., Tisch, R.M., Johnston, R.E., Serody, J.S. Alphaviral vector-transduced dendritic cells are successful therapeutic vaccines against neu-overexpressing tumors in wild-type mice. Vaccine 2007, 25, 6604-6612. [CrossRef]
96. Lyons, J.A., Sheahan, B.J., Galbraith, S.E., Mehra, R., atkins, G.J., Fleeton, M.N. Inhibition of angiogenesis by a Semliki Forest virus vector expressing VEGFR-2 reduces tumour growth and metastasis in mice. Gene Ther. 2007, 14, 503-513. [CrossRef]
97. Daemen, T., Riezebos-Brilman, A., Bungener, L., Regts, J., Dontje, B., Wiltschut, J. Eradication of established HPV16-transformed tumours after immunisation with recombinant Semliki Forest virus expressing a fusion protein of E6 and E7. Vaccine 2003, 21, 1082-1088. [CrossRef]
98. Van de Wall, S., Walczak, M., van Rooij, N., Hoogeboom, B.N., Meijerhof, T., Nijman, H.W., Daemen, T. Tattoo delivery of a Semliki Forest virus based vaccine encoding Human Papillomavirus E6 and E7. Vaccines 2015, 3, 221-238. [CrossRef]
99. Velders, M.P., McElhiney, S., Cassetti, M.C., Eiben, G.L., Higgins, T., Kovacs, G.R., Elmishad, A.G., Kast, W.M., Smith, L.R. Eradication of established tumors by vaccination with Venezuelan equine encephalitis virus replicon particles delivering human papillomavirus 16 E7 RNA. Cancer Res. 2001, 61, 7861-7867.
100. Ying, H., Zaks, T.Z., Wang, R.F., Irvine, K.R., Kammula, U.S., Marincola, F.M., Leitner, W.W., Restifo, N.P. Cancer therapy using a self-replicating RNA vaccine. Nat. Med. 1999, 5, 823-827.
101. Granot, T., Yamanashi, Y., Meruelo, D. Sindbis viral vectors transiently deliver tumor-associated antigens to lymph nodes and elicit diversified antitumor CD8+ T-cell immunity. Mol. Ther. 2014, 22, 112-122. [CrossRef]
102. Rodriguez-Madoz, J.R., Prieto, J., Smerdou, C. Semliki forest virus vectors engineered to express higher IL-12 levels induce efficient elimination of murine colon adenocarcinomas. Mol. Ther. 2005, 12, 153-163. [CrossRef]
103. Smyth, J.W., Fleeton, M.N., Sheahan, B.J., Atkins, G.J. Treatment of rapidly growing K-BALB and CT26 mouse tumors using Semliki Forest virus recombinant particles. Gene Ther. 2005, 12, 147-159. [CrossRef]
104. Chikkanna-Gowda, C.P., McNally, S., Sheahan, B.J., Fleeton, M.N., Atkins, G.J. Inhibition of murine K-BALB and CT26 tumour growth using a Semliki Forest virus vector with enhanced expression of IL-18. Oncol. Rep. 2006, 16, 713-719. [CrossRef]
105. Rodriguez-Madoz, J.R., Liu, K.H., Quetglas, J.I., Ruiz-Guillen, M., Otano, I., Crettaz, J., Butler, S.D., Bellezza, C.A., Dykes, N.L., Tennant, B.C., et al. Semliki forest virus expressing interleukin-12 induces antiviral and antitumoral responses in woodchucks with chronic viral hepatitis and hepatocellular carcinoma. J. Virol. 2009, 83, 12266-12278. [CrossRef]
106. Rodriguez-Madoz, J.R., Zabala, M., Alfaro, M., Prieto, J., Kramer, M.G., Smerdou, C. Short-term intratumoral interleukin-12 expressed from an alphaviral vector is sufficient to induce an efficient antitumoral response against spontaneous hepatocellular carcinomas. Hum. Gene Ther. 2014, 25, 132-143. [CrossRef]
107. Draghiciu, O., Boerma, A., Hoogeboom, B.N., Nijman, H.W., Daemen, T. A rationally designed combined treatment with an alphavirus-based cancer vaccine, sunitinib and low-dose tumor irradiation completely blocks tumor development. Oncoimmunology 2015, 4, e1029699. [CrossRef]
108. Cheng, W.F., Lee, C.N., Su, Y.N., Chai, C.Y., Chang, M.C., Polo, J.M., Hung, C.F., Wu, T.C., Hsieh, C.Y., Chen, C.A. Sindbis virus replicon particles encoding calreticulin linked to a tumor antigen generate long-term tumor-specific immunity. Cancer Gene. Ther. 2006, 13, 873-885. [CrossRef]
109. Murphy, A.M., Morris-Downes, M.M., Sheahan, B.J., Atkins, G.J. Inhibition of human lung carcinoma cell growth by apoptosis induction using Semliki Forest virus recombinant particles. Gene Ther. 2000, 7, 1477-1482. [CrossRef]
110. Yin, X., Wang, W., Zhu, X., Wang, Y., Wu, S., Wang, Z., Wang, L., Du, Z., Gao, J., Yu, J. Synergistic antitumor efficacy of combined DNA vaccines targeting tumor cells and angiogenesis. Biochem. Biophys. Res. Commun. 2015, 465, 239-244. [CrossRef]
111. Avogadri, F., Merghoub, T., Maughan, M.F., Hirschhorn-Cymerman, D., Morris, J., Ritter, E., Olmsted, R., Houghton, A.N., Wolchok, J.D. Alphavirus replicon particles expressing TRP-2 provide potent therapeutic effect on melanoma through activation of humoral and cellular immunity. PLoS ONE 2010, 5, e12670. [CrossRef]
112. Goldberg, S.M., Bartido, S.M., Gardner, J.P., Guevara-Patino, J.A., Montgomery, S.C., Perales, M.A., Maughan, M.F., Dempsey, J., Donovan, G.P., Olson, W.C., et al. Comparison of two cancer vaccines targeting tyrosinase: Plasmid DNA and recombinant alphavirus replicon particles. Clin. Cancer Res. 2005, 11, 8114-8121. [CrossRef]
113. Tseng, J.C., Levin, B., Hurtado, A., Yee, H., de Castro, I.P., Jimenez, M., Shamamian, P., Jin, R., Novick, R.P., Pellicier, A., et al. Systemic tumor targeting and killing by Sindbis viral vectors. Nat. Biotechnol. 2004, 22, 70-77. [CrossRef]
114. Klimp, A.H., van der Vaart, E., Lansink, P.O., Withoff, S., de Vries, E.G., Scherphof, G.L., Wilschut, J., Daemen, T. Activation of peritoneal cells upon in vivo transfection with a recombinant alphavirus expressing GM-CSF. Gene Ther. 2001, 8, 300-307. [CrossRef]
115. Durso, R.J., Andjelic, S., Gardner, J.P., Margitich, D.J., Donovan, G.P., Arrigale, R.R., Wang, X., Maughan, M.F., Talarico, T.L., Olmsted, R.A., et al. A novel alphavirus vaccine encoding prostate-specific membrane antigen elicits potent cellular and humoral immune responses. Clin. Cancer Res. 2007, 13, 3999-4008. [CrossRef]
116. Garcia-Hernandez, M.L., Gray, A., Hubby, B., Kast, W.M. In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: A candidate antigen for treating prostate cancer. Cancer Res. 2007, 67, 1344-1351. [CrossRef]
117. Garcia-Hernandez, M.L., Gray, A., Hubby, B., Klinger, O.J., Kast, W.M. Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity. Cancer Res. 2008, 68, 861-869. [CrossRef]
118. Riabov, V., Tretyakova, I., Alexander, R.B., Pushko, P., Klyushnenkova, E.N. Anti-tumor effect of the alphavirus-based virus-like particle vector expressing prostate-specific antigen in a HLA-DR transgenic mouse model of prostate cancer. Vaccine 2015, 33, 5386-5395. [CrossRef]
119. Colmenero, P., Liljeström, P., Jondal, M. Induction of P815 tumor immunity by recombinant Semliki Forest virus expressing the P1A gene. Gene Ther. 1999, 6, 1728-1733. [CrossRef]
120. Morse, M.A., Hobeika, A.C., Osada, T., Berglund, P., Hubby, B., Negri, S., Niedzwiecki, D., Devi, G.R., Burnett, B.K., Clay, T.M., et al. An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer. J. Clin. Investig. 2010, 120, 3234-3241. [CrossRef]
121. Gomes, I.M., Maia, C.J., Santos, C.R. STEAP proteins: From structure to applications in cancer therapy. Mol. Cancer Res. 2012, 10, 573-587. [CrossRef]
122. Bins, A.D., Jorritsma, A., Wolkers, M.C., Hung, C.F., Wu, T.C., Schumacher, T.N., Haanen, J.B. A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression. Nat. Med. 2005, 11, 899-904. [CrossRef]
123. Vähä-Koskela, M.J., Kallio, J.P., Jansson, L.C., Heikkilä, J.E., Zakhartchenko, V.A., Kallajoki, M.A., Kähäri, V.M., Hinkkanen, A.E. Oncolytic capacity of attenuated replicative Semliki Forest virus in human melanoma xenografts in severe combined immunodeficient mice. Cancer Res. 2006, 66, 7185-7194. [CrossRef]
124. Chikkanna-Gowda, C.P., Sheahan, B.J., Fleeton, M.N., Atkins, G.J. Regression of mouse tumours and inhibition of metastases following administration of a Semliki Forest virus vector with enhanced expression of IL-12. Gene Ther. 2005, 12, 1253-1263. [CrossRef]
125. Huttner, A., Dayer, J.A., Yerly, S., Combescure, C., Auderset, F., Desmeules, J., Eickmann, M., Finckh, A., Goncalves, A.R., Hooper, J.W., et al. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: A randomised double-blind, placebo-controlled phase 1/2 trial. Lancet Infect. Dis. 2015, 15, 1156-1166. [CrossRef]
126. Fuchs, J.D., Frank, I., Elizaga, M.L., Allen, M., Frahm, N., Kochar, N., Li, S., Edupuganti, S., Kalams, S.A., Tomaras, G.D., et al. First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Vesicular Stomatitis Virus Human Immunodeficiency Virus-1 gag Vaccine (HVTN 090). Open Forum Infect. Dis. 2015. [CrossRef]
127. Lundstrom, K. Biology and application of alphaviruses in gene therapy. Gene Ther. 2005, 12, S92-S597. [CrossRef]
128. Ren, H., Boulikas, T., Lundstrom, K., Söling, A., Warnke, P.C., Rainov, N.G. Immunogene therapy of recurrent glioblastoma multiforme with a liposomally encapsulated replication incompetent Semliki Forest virus vector carrying the human interleukin-12 gene—A phase I/II protocol. J. Neurooncol. 2003, 64, 147-154. [CrossRef]
129. Slovin, S.F., Kehoe, M., Durso, R., Fernandez, C., Olson, W., Gao, J.P., Israel, R., Scher, H.I., Morris, S. A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in subjects with prostate cancer. Vaccine 2013, 31, 943-949. [CrossRef]
130. Alba, R., Bosch, A., Chillon, M. Gutless adenovirus: Last-generation adenovirus for gene therapy. Gene Ther. 2005, 12, S18-S27. [CrossRef]
131. Schiedner, G., Morral, N., Parks, R.S., Wu, Y., Koopmans, S.C., Langston, C., Graham, F.L., Beuadet, A.L., Kochanek, S. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat. Genet. 1998, 18, 180-183. [CrossRef]
132. Wang, F., Wang, Z., Tian, H., Qi, M., Zhai, Z., Li, S., Li, R., Zhang, H., Wang, W., Fu, S., et al. Biodistribution and safety assessment of bladder cancer specific oncolytic adenovirus in subcutaneous xenografts tumor model in nude mice. Curr. Gene Ther. 2012, 12, 67-76. [CrossRef]
133. Andtbacka, R.H., Agarwala, S.S., Ollila, D.W., Hallmeyer, S., Milhem, M., Amatruda, T., Nemunaitis, J.J., Harrington, K.J., Chen, L., Shilkrut, M., et al. Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma. Head Neck. 2016. [CrossRef]
134. Zhang, L., Tatsuya, T., Nishiyama, Y. Oncotarget Strategies For Herpes Simplex Virus-1. Curr. Gene Ther. 2016, 16, 130-143. [CrossRef]
135. Chahal, J.S., Khan, O.F., Cooper, C.L., McPartlan, J.S., Tsosie, J.K., Tilley, L.D., Sidik, S.M., Lourido, S., Langer, R., Bavari, S., et al. Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose. Proc. Natl. Acad. Sci. USA 2016, 113, E4133-E4142. [CrossRef]
136. Leitner, W.W., Ying, H., Driver, D.A., Dubensky, T.W., Restifo, N.P. Enhancement of tumor-specific immune response with plasmid DNA replicon vectors. Cancer Res. 2000, 60, 51-55.